×
About 20,936 results

ALLMedicine™ Parkinson Disease Center

Research & Reviews  10,019 results

Evaluation of the efficacy of physical therapy on cognitive decline at 6-month follow-u...
https://doi.org/10.1007/s40520-021-01865-4 10.1002/mds.23394 10.1002/mds.23823 10.1002/mds.26352 10.1016/S0140-6736(17)31363-6 10.3233/NRE-192714 10.1212/WNL.0000000000002145 10.3233/JPD-181484 10.3390/brainsci3010087 10.1002/mds.26484 10.1186/2047-9158-3-5 10.1371/journal.pone.0193113 10.11138/fneur/2016.31.1.025 10.1016/j.neuroscience.2011.11.054 10.1016/j.brainresbull.2014.09.006 10.2217/nmt-2019-0025 10.1016/j.gaitpost.2018.12.009 10.1080/00222895.2013.834288 10.1016/j.physio.2012.06.004 10.1249/MSS.0000000000000144 10.1002/mds.26291 10.1016/j.bandc.2018.01.002 10.4172/2161-0460.1000475 10.1002/mds.26424 10.1212/wnl.17.5.427 10.1002/mds.24893 10.1111/j.1468-1331.1996.tb00423.x 10.1007/s10072-014-1921-3 10.1159/000117297 10.1007/s10072-005-0443-4 10.1007/BF01997792 10.1002/mds.22340 10.1111/j.1532-5415.1986.tb05480.x 10.1056/NEJM198301273080401 10.1212/WNL.0000000000000644 10.3389/fnagi.2017.00358 10.1016/S1474-4422(13)70123-6 10.1097/PSY.0b013e3181d14633 10.1016/j.neubiorev.2018.09.018 10.3233/BPL-160039 10.1177/1545968315600272 10.3389/fnhum.2014.00985 10.1212/WNL.0b013e318225ab66 10.3389/fnins.2014.00187 10.1515/revneuro-2012-0067
Aging Clinical and Experimental Research; Avenali M, Picascia M et. al.

May 12th, 2021 - In Parkinson's disease (PD), physical activity may represent a possible non-pharmacological intervention not only for improving motor symptoms but also for modulating cognitive impairment. To evaluate the efficacy of an intensive physical program ...

α4β2* Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease Gait-Balanc...
https://doi.org/10.1002/ana.26102
Annals of Neurology; Albin RL, Müller MLTM et. al.

May 12th, 2021 - Attentional deficits following degeneration of brain cholinergic systems contribute to gait-balance deficits in Parkinson disease (PD). As a step towards assessing if α4β2* nicotinic acetylcholine receptor (nAChR) stimulation improves gait-balance...

Motor Dysfunction in REM Sleep Behavior Disorder: A Rehabilitation Framework for Prodro...
https://doi.org/10.1177/15459683211011238
Neurorehabilitation and Neural Repair; Summers RLS, Rafferty MR et. al.

May 12th, 2021 - Parkinson disease (PD) and other related diseases with α-synuclein pathology are associated with a long prodromal or preclinical stage of disease. Predictive models based on diagnosis of idiopathic rapid eye movement (REM) sleep behavior disorder ...

Chaperone-mediated autophagy controls the turnover of E3 ubiquitin ligase MARCHF5 and r...
https://doi.org/10.1080/15548627.2020.1848128
Autophagy Nie T, Tao K et. al.

May 10th, 2021 - As a highly dynamic organelle, mitochondria undergo constant fission and fusion to change their morphology and function, coping with various stress conditions. Loss of the balance between fission and fusion leads to impaired mitochondria function,...

What Is the Clinical Correlation of Cardiac Noradrenergic Denervation in Parkinson Dise...
https://doi.org/10.1212/WNL.0000000000011805
Neurology Lamotte G, Benarroch EE

May 10th, 2021 - What Is the Clinical Correlation of Cardiac Noradrenergic Denervation in Parkinson Disease?|2021|Lamotte G,Benarroch EE,|

see more →

Guidelines  155 results

Gocovri Clinical Data
https://www.gocovrihcp.com/clinical-data/
Gocovrihcp.com

May 27th, 2020 - The efficacy and safety of GOCOVRI® 274 mg were evaluated in two Phase 3, randomized, placebo-controlled trials

Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms – An fMRI study
https://www.jns-journal.com/article/S0022-510X(20)30242-2/pdf
Journal of Neurological Sciences;

May 26th, 2020 - Parkinson's disease (PD) patients develop levodopa induced dyskinesia with disease progression from sensitization of central pathways. Pain pathways are also impacted with suggestions dyskinetic patients may process pain differently.

White matter hyperintensities and risk of levodopa‐induced dyskinesia in Parkinson’s disease
https://onlinelibrary.wiley.com/doi/full/10.1002/acn3.50991
Annals of Clinical and Translational Neurology;

Feb 6th, 2020 - To investigate whether the burden of white matter hyperintensities (WMHs) is associated with the risk of developing levodopa‐induced dyskinesia (LID) in Parkinson’s disease (PD).

Blood Flow and Glucose Metabolism Dissociation in the Putamen Is Predictive of Levodopa Induced Dyskinesia in Parkinson's Disease Patients
https://www.frontiersin.org/articles/10.3389/fneur.2019.01217/full
Frontiers in Neurology;

Nov 20th, 2019 - The forefront treatment of Parkinson's disease (PD) is Levodopa. When patients are treated with Levodopa cerebral blood flow is increased while cerebral metabolic rate is decreased in key subcortical regions including the putamen. This phenomenon ...

Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials
https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd181565
Journal of Parkinson's Disease;

Jul 29th, 2019 - Evaluate prevalence of troublesome dyskinesia and OFF through the day, assessed by 30-minute intervals, as well as the mean number and duration of troublesome dyskinesia and OFF episodes, transitions between PD states, and effects of Gocovri® (ama...

see more →

Drugs  15 results see all →

Clinicaltrials.gov  10,269 results

Evaluation of the efficacy of physical therapy on cognitive decline at 6-month follow-u...
https://doi.org/10.1007/s40520-021-01865-4 10.1002/mds.23394 10.1002/mds.23823 10.1002/mds.26352 10.1016/S0140-6736(17)31363-6 10.3233/NRE-192714 10.1212/WNL.0000000000002145 10.3233/JPD-181484 10.3390/brainsci3010087 10.1002/mds.26484 10.1186/2047-9158-3-5 10.1371/journal.pone.0193113 10.11138/fneur/2016.31.1.025 10.1016/j.neuroscience.2011.11.054 10.1016/j.brainresbull.2014.09.006 10.2217/nmt-2019-0025 10.1016/j.gaitpost.2018.12.009 10.1080/00222895.2013.834288 10.1016/j.physio.2012.06.004 10.1249/MSS.0000000000000144 10.1002/mds.26291 10.1016/j.bandc.2018.01.002 10.4172/2161-0460.1000475 10.1002/mds.26424 10.1212/wnl.17.5.427 10.1002/mds.24893 10.1111/j.1468-1331.1996.tb00423.x 10.1007/s10072-014-1921-3 10.1159/000117297 10.1007/s10072-005-0443-4 10.1007/BF01997792 10.1002/mds.22340 10.1111/j.1532-5415.1986.tb05480.x 10.1056/NEJM198301273080401 10.1212/WNL.0000000000000644 10.3389/fnagi.2017.00358 10.1016/S1474-4422(13)70123-6 10.1097/PSY.0b013e3181d14633 10.1016/j.neubiorev.2018.09.018 10.3233/BPL-160039 10.1177/1545968315600272 10.3389/fnhum.2014.00985 10.1212/WNL.0b013e318225ab66 10.3389/fnins.2014.00187 10.1515/revneuro-2012-0067
Aging Clinical and Experimental Research; Avenali M, Picascia M et. al.

May 12th, 2021 - In Parkinson's disease (PD), physical activity may represent a possible non-pharmacological intervention not only for improving motor symptoms but also for modulating cognitive impairment. To evaluate the efficacy of an intensive physical program ...

α4β2* Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease Gait-Balanc...
https://doi.org/10.1002/ana.26102
Annals of Neurology; Albin RL, Müller MLTM et. al.

May 12th, 2021 - Attentional deficits following degeneration of brain cholinergic systems contribute to gait-balance deficits in Parkinson disease (PD). As a step towards assessing if α4β2* nicotinic acetylcholine receptor (nAChR) stimulation improves gait-balance...

Motor Dysfunction in REM Sleep Behavior Disorder: A Rehabilitation Framework for Prodro...
https://doi.org/10.1177/15459683211011238
Neurorehabilitation and Neural Repair; Summers RLS, Rafferty MR et. al.

May 12th, 2021 - Parkinson disease (PD) and other related diseases with α-synuclein pathology are associated with a long prodromal or preclinical stage of disease. Predictive models based on diagnosis of idiopathic rapid eye movement (REM) sleep behavior disorder ...

Chaperone-mediated autophagy controls the turnover of E3 ubiquitin ligase MARCHF5 and r...
https://doi.org/10.1080/15548627.2020.1848128
Autophagy Nie T, Tao K et. al.

May 10th, 2021 - As a highly dynamic organelle, mitochondria undergo constant fission and fusion to change their morphology and function, coping with various stress conditions. Loss of the balance between fission and fusion leads to impaired mitochondria function,...

What Is the Clinical Correlation of Cardiac Noradrenergic Denervation in Parkinson Dise...
https://doi.org/10.1212/WNL.0000000000011805
Neurology Lamotte G, Benarroch EE

May 10th, 2021 - What Is the Clinical Correlation of Cardiac Noradrenergic Denervation in Parkinson Disease?|2021|Lamotte G,Benarroch EE,|

see more →

News  465 results

A Breakthrough in Parkinson Disease and New Data on Treating Stroke
https://www.medscape.com/viewarticle/933212

Jul 12th, 2020 - This transcript has been edited for clarity. Dear colleagues, I'm Christoph Diener, a neurologist from the University of Duisburg-Essen in Germany, presenting six very interesting publications from February 2020 in the fields of stroke, multiple s...

The Gut a New Therapeutic Target for Brain Disorders?
https://www.staging.medscape.com/viewarticle/931719

Jun 3rd, 2020 - Changes in the mucus that lines the gastrointestinal (GI) tract may contribute to bacterial imbalance in the gut and exacerbate core symptoms of autism, Parkinson disease (PD), Alzheimer disease (AD), and multiple sclerosis (MS), new research sugg...

The Gut a New Therapeutic Target for Brain Disorders?
https://www.medscape.com/viewarticle/931719

Jun 3rd, 2020 - Changes in the mucus that lines the gastrointestinal (GI) tract may contribute to bacterial imbalance in the gut and exacerbate core symptoms of autism, Parkinson disease (PD), Alzheimer disease (AD), and multiple sclerosis (MS), new research sugg...

Gocovri Clinical Data
https://www.gocovrihcp.com/clinical-data/
Gocovrihcp.com

May 27th, 2020 - The efficacy and safety of GOCOVRI® 274 mg were evaluated in two Phase 3, randomized, placebo-controlled trials

Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms – An fMRI study
https://www.jns-journal.com/article/S0022-510X(20)30242-2/pdf
Journal of Neurological Sciences;

May 26th, 2020 - Parkinson's disease (PD) patients develop levodopa induced dyskinesia with disease progression from sensitization of central pathways. Pain pathways are also impacted with suggestions dyskinetic patients may process pain differently.

see more →

Patient Education  13 results see all →